Oxford Immunotec: Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit

Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit Agreement
includes payment of $27.5 million to Oxford, royalty-free license to QIAGEN and
dismissal of all pending litigation 

OXFORD, United Kingdom and MARLBOROUGH, Mass., 2017-12-15 22:04 CET (GLOBE
NEWSWIRE) --
Oxford Immunotec Ltd. (Nasdaq:OXFD) and QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt
Stock Exchange:QIA) announced today that they have reached a settlement in the
lawsuit in the U.S. District Court for the District of Massachusetts in Boston
(15-cv-13124-NMG) alleging patent infringement in relation to QIAGEN's
QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus products. 

Under terms of the agreement, all pending claims between Oxford and QIAGEN and
the co-defendants have been resolved. As part of the settlement, Oxford has
granted QIAGEN a royalty-free, non-exclusive license that extends to all
current and future customers of QuantiFERON-TB Gold and QuantiFERON-TB Gold
Plus in exchange for a one-time, lump-sum payment of $27.5 million.  The
settlement includes general releases of all parties with no admissions of
wrongdoing. 

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company
focused on developing and commercializing proprietary tests for the management
of underserved immune-regulated conditions.  The Company's first product is the
T-SPOT.TB test, which is used to test for tuberculosis infection.  The
T-SPOT.TB test has been approved for sale in over 50 countries, including the
United States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China.  The Company's second product line is a range of assays for tick-borne
diseases, such as Lyme disease, obtained through the acquisitions of Imugen and
Immunetics.  Also obtained through these acquisitions is the Company's third
product line focused on screening for Babesia in donated blood, for which the
Company is currently seeking FDA licensure.  The Company's fourth product line
is focused on the transplantation market.  The Company is headquartered near
Oxford, U.K. and in Marlborough, Mass.  Additional information can be found at
www.oxfordimmunotec.com. 

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. 
Immunetics is a trademark of Immunetics, Inc. 

Forward-Looking Statements

This release contains forward-looking statements that involve risks and
uncertainties, including statements about our anticipated plans, objectives,
intentions, including effects on future financial and operating results,
prospects for sales of our products and other statements that are not
historical facts. The forward-looking statements in this release are based on
current expectations, assumptions and data available as of the date of this
release and are subject to known and unknown risks and uncertainties that could
cause actual results to differ materially from those expressed or implied by
such statements, including but not limited to: decisions by regulatory
authorities, hospitals and other health care institutions, laboratories,
physicians, patients and third party payers that could affect the Company's
business and prospects; as well as our ability to expeditiously and
successfully expand our sales and distribution networks. The risks included
above are not exhaustive. Other factors that could adversely affect our
business and prospects are described under the "Risk Factors" section in our
filings with the Securities and Exchange Commission ("SEC"). Our filings are
available for free by visiting the investor section of our website,
www.oxfordimmunotec.com, or the SEC's website, www.sec.gov. 

Investors should give careful consideration to these risks and uncertainties.
Forward-looking statements contained herein are based on current expectations
and assumptions and currently available data and are neither predictions nor
guarantees of future events or performance. You should not place undue reliance
on forward-looking statements contained herein, which speak only as of the date
of this release. We do not undertake to update or revise any forward-looking
statements after they are made, whether as a result of new information, future
events, or otherwise, except as required by applicable law. 

CONTACT:

For Media and Investor Inquiries:
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: [phone]
[e-mail]